Literature DB >> 25023770

Childhood very severe pneumonia and meningitis-related hospitalization and death in Yemen, before and after introduction of H. influenzae type b (Hib) vaccine.

S M Banajeh1, O Ashoor2, A S Al-Magramy2.   

Abstract

Haemophilus influenzae type b (Hib) vaccine was included in the Yemen immunization programme in 2005. This study compared the rates of very severe pneumonia and all-cause meningitis hospitalization and death, before and after introduction of conjugate Hib vaccine, and reports the results of the 2010 bacterial meningitis surveillance. A retrospective analysis was made of data collected for 2000-2010 for all children aged 2-60 months in the main children's hospital in Sana'a. Compared with the pre-Hib vaccination period, the post-Hib period showed significant and impressive reductions in the rates of hospitalization and death for all-cause meningitis. However, hospitalization and death for very severe pneumonia improved only modestly, and there was evidence of a decreasing but non-significant trend indicting that very severe pneumonia was a non-specific endpoint with multi-etiologies (both viral and bacterial). Very severe pneumonia remains the leading cause of severe morbidity and death for young children, particularly those aged < 12 months.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25023770

Source DB:  PubMed          Journal:  East Mediterr Health J        ISSN: 1020-3397            Impact factor:   1.628


  2 in total

Review 1.  Research progress of health care in Yemeni children during the war: review.

Authors:  Yahya Ali Gaber; Rukaih Al-Sanabani; Dhekra Amin Annuzaili; Abdullah Al-Danakh; Li Chun Ling
Journal:  Prim Health Care Res Dev       Date:  2022-09-12       Impact factor: 1.792

2.  Emergency treatment and nursing of children with severe pneumonia complicated by heart failure and respiratory failure: 10 case reports.

Authors:  Wanli Li; Xinjiang An; Mingyu Fu; Chunli Li
Journal:  Exp Ther Med       Date:  2016-07-29       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.